- 产品描述
- 产品组分
- 文件资源
- 营销中心
- 注意事项
- FAQ
- 文献追踪
-
曲唑(以前称为 CGS-20267;商品名:Femara;Letoval)是第三代非甾体芳香酶抑制剂,无细胞测定中 IC50 为 0.07-20 nM,具有抗癌活性。作为第三代芳香酶抑制剂,来曲唑选择性、可逆地抑制芳香酶,可能导致雌激素依赖性乳腺癌细胞的生长抑制。来曲唑给药可以减少脊柱突触和轴突的生长,并且还会减少雌激素受体(ER)的表达。来曲唑被证明可通过响应减少的雌激素 (E) 反馈来促进下丘脑垂体轴释放 FSH。来曲唑于1996年被批准用于治疗绝经后女性激素受体阳性或受体状态未知的局部或转移性乳腺癌。
靶点 Aromatase (IC50 = 11.5 nM)
体外研究 (In Vitro) 来曲唑(0.1-100 nM;24-96 小时)以剂量和时间依赖性方式强烈抑制 MCF-7 上皮乳腺癌细胞的发育 [2]。来曲唑 (10 nM) 会显着抑制睾酮对 MCF-7 细胞生长的刺激作用 [2]。在 MCF-7 细胞中,来曲唑(10 nM;24-48 小时)可减少释放的金属蛋白酶(MMP-2 和 MMP-9)的量 [2]。
体内研究 (In Vivo) 用来曲唑(3-300 μg/kg;每天口服一次,持续六周)治疗的大鼠显示出抗肿瘤作用[3]。
在体内,在ACTH治疗的大鼠中,口服4 mg/kg剂量的CGS 20267不影响皮质酮或醛固酮的血浆水平(比体内芳香化酶抑制的ED50高1000倍)。在成年雌性大鼠中,每天口服1mg/kg的14天治疗完全中断了卵巢周期性,并将子宫重量抑制到卵巢切除术后14天的水平。在携带雌激素依赖性DMBA诱导的乳腺肿瘤的成年雌性大鼠中,每天口服0.1mg/kg,持续42天,可使治疗开始时出现的肿瘤几乎完全消退。因此,相比之下,CGS 16949A和CGS 20267在体外和体内抑制雌激素生物合成方面都非常有效。它们之间的显著区别在于,与CGS 16949A不同,CGS 20267在体外或体内不影响肾上腺类固醇生成,其浓度和剂量比抑制雌激素生物合成所需的浓度和剂量高几个数量级[1]。酶活实验 CGS 20267是一种新的非甾体化合物,在体外(IC50为11.5 nM)和体内(ED50为1-3微克/千克口服)均能有效抑制芳香化酶,CGS 20267在0.1微M下最大限度地抑制LH刺激的仓鼠卵巢组织中雌二醇的产生,IC50为0.02微M,对高达350微M的孕酮产生没有显著影响。在体外ACTH刺激的大鼠肾上腺组织中,醛固酮的产生受到抑制,IC50为210微M(比雌二醇产生的IC50高10000倍);在350微摩尔浓度下,未观察到对皮质酮生成的显著影响[1]。
细胞实验 细胞活力测定[2]
细胞类型: MCF-7 细胞
测试浓度: 0.1、1、10、100 nM
孵育持续时间:24、48、96小时
实验结果:以剂量和时间依赖性方式抑制细胞生长。动物实验 Animal/Disease Models: Adult female rats bearing mammary tumors[3]
Doses: 3, 10, 30, 100, 300 μg/kg
Route of Administration: po (oral gavage) one time/day for 6 weeks
Experimental Results: Induced complete regression of mammary tumors, with an ED50 of 10-30 μg/kg/day.参考文献 [1]. Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7.
[2]. Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104(2):155-60.
[3]. Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):633-6.其他信息 Letrozole is a member of triazoles and a nitrile. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor.
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
Letrozole is an Aromatase Inhibitor. The mechanism of action of letrozole is as an Aromatase Inhibitor.
Letrozole is a nonsteroidal inhibitor of aromatase which effectively blocks estrogen synthesis in postmenopausal women and is used as therapy of estrogen receptor positive breast cancer, usually after resection and after failure of tamoxifen. Letrozole has been associated with a low rate of serum enzyme elevations during therapy and rare instances of clinically apparent liver injury.
Letrozole is a nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.
Letrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer. Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems. Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.
Letrozole is 99.9% orally bioavailable. A 2.5mg oral dose reaches a Cmax of 104nmol/L with a Tmax of 8.10h, and an AUC of 7387nmol\*h/L.
The terminal elimination half life of letrozole is approximately 42h in healthy volunteers, but longer in breast cancer patients.*注: 文献方法仅供参考, IVDSHOW并未独立验证这些方法的准确性。
分子式 C17H11N5
分子量 285.3
精确质量 263.142
元素分析 C, 71.57; H, 3.89; N, 24.55
CAS号 112809-51-5
相关CAS号 Letrozole-d4;1133712-96-5
PubChem CID 3902
外观&性状 Typically exists as white to off-white solids at room temperature
密度 1.1±0.1 g/cm3
沸点 472.0±55.0 °C at 760 mmHg
熔点 181-183ºC
闪点 214.2±24.5 °C
蒸汽压 0.0±1.2 mmHg at 25°C
折射率 1.615
LogP 3.7
tPSA 78.29
SMILES N1(C([H])=NC([H])=N1)C([H])(C1C([H])=C([H])C(C#N)=C([H])C=1[H])C1C([H])=C([H])C(C#N)=C([H])C=1[H]
InChi Key HPJKCIUCZWXJDR-UHFFFAOYSA-N
InChi Code InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
化学名 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
别名 Abbreviation; CGS 20267; CGS20267; CGS-20267; LTZ; Trade name: Femara; Letoval; Femara; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozol;
HS Tariff Code 2934.99.9001
存储方式 Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
-
产品组分
内容 型号 规格 储存温度
来曲唑(Letrozole) V1798-01 50mg -20°C 来曲唑(Letrozole) V1798-02 100mg -20°C 来曲唑(Letrozole) V1798-03 250mg -20°C 来曲唑(Letrozole) V1798-04 500mg -20°C 来曲唑(Letrozole) V1798-05 1g -20°C 来曲唑(Letrozole) V1798-06 2g -20°C 来曲唑(Letrozole) V1798-07 5g -20°C 来曲唑(Letrozole) V1798-08 10g -20°C 来曲唑(Letrozole) V1798-09 1ml(10mM in DMSO) -20°C 操作手册
1 1 常温
-
注意事项
保存建议 厂家推荐蓝冰运输。当您收到产品后,按照说明书建议保存于-20°C。 -
FAQ

猜你喜欢
在线留言
如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!
艾维缔官网
艾德官网
B站IVDSHOW
抖音军哥聊表观
视频号艾维缔
小红书艾维缔
快手表观盒子
表观遗传学
联系我们

